Non-Insulin Injectable Therapies : Newer injectable therapies, including those not based on the incretin system, are in the pipeline, targeting different biological pathways involved in T2D pathogenesis
What does the glucagon receptor add in GLP-3(Reta) research that the dual agonist cannot produce
Disclosures: Jacob Romano: Nothing to Disclose, Jessica Burnside: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support, Keyur Patel: Novo-Nordisk: Consultant, Gilead Sciences: Consultant, Merck: Consultant, Resalis: Advisor, Alnoor Ramji: Nothing to Disclose, Mark Swain: Ipsen: Advisor, Abbott: Advisor, Advanz: Advisor, Novo Nordisk: Advisor, GSK: Advisor, Ipsen: clinical trial research grant support, Novo Nordisk: clinical trial research grant support, Madrigal: clinical trial research grant support, Kowa: clinical trial research grant support, Gilead: clinical trial research grant support, Abbvie: clinical trial research grant support, Merck: clinical trial research grant support, Galectin: clinical trial research grant support, Sahar Saeed: Novo Nordisk: Consultant 1200 HELICOBACTER PYLORI CAGA/VACAS1-M1 STRAIN IS ASSOCIATED WITH HIGH RISK OF FIBROSIS IN METABOLIC-DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Fernando Barreyro 1 Facundo Maiorana 1 Magali Neschuk 1 Maria Viriginia Caronia 1 Karina Elizondo 2 Adolfo Schneider 2 Georgina Veron 2 Pedro Dario Zapata 1 , 1 National University of Misiones, 2 Barcelo University Institute of Health Sciences Background: Recent studies have suggested an association between H
Seventy percent ethanol extract was provided at doses of 300, 600 and 1200 mg/kg to genetically obese in Zucker rats resulting in a reduction of circulating GLP-1 by acting on GLP-1 receptors [32]
